Generic Name and Formulations:
Netarsudil 0.02%; oph soln; contains benzalkonium chloride.
Aerie Pharmaceuticals, Inc.
Indications for RHOPRESSA:
Open-angle glaucoma. Ocular hypertension.
≥18yrs: Instill 1 drop into the affected eye(s) once daily in the PM.
<18yrs: not established.
Concurrent corneal disease or disruption of the ocular epithelial surface. Contact lenses (remove; may reinsert lenses 15mins after administration). Pregnancy. Nursing mothers.
Rho kinase inhibitor.
Allow at least 5mins between application of other topical oph agents.
Conjunctival hyperemia, corneal verticillata, instillation site pain, conjunctival hemorrhage; bacterial keratitis.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Link Identified Between Cured Meat and Mania in Bipolar Disorder
- Early Risk Factors for Bipolar Disorder Found in Offspring of BD Parents
- First-Episode Delusional Disorder vs Schizophrenia: Assessment of Outcomes
- Daily Drinking Associated With Increased Mortality Risk
- Probiotics, Depression, and the Role of Inflammation
- The Opioid System: The Foundation for Social Risk and Reward
- Correctional Psychiatry: Challenges and Rewards
- Those Left Behind: Working With Suicide-Bereaved Families
- Is Mandatory Reporting of Child Maltreatment in the Best Interests of the Child?
- The Impact of Deafness on Hallucinations and Delusions
- High Risk for Anxiety, Depression, and Stress Observed Among Single Mothers
- Self-Harm, Suicidality Among Adolescents Associated With Poor Outcomes, Recurrent Clinical Care
- Moderate Association Between Sociocognitive Functioning and Thought Disorder in Schizophrenia
- Psychotropic Medications May Improve Pregnancy Outcomes in Bipolar Disorder
- Schizophrenia Polygenetic Risk Score as a Predictor of Bipolar Disorder With Psychosis